Faculty & Staff at TUC

Paul J  Perry

Paul J. Perry

College: COP

Department: Clinical Sciences

Title: Professor

Phone: (707) 638-5934

Fax: (707) 638-5959

E-Mail: paul.perry@tu.edu

Office: Administration and Faculty 2 (H-84), Rm. 110

Dr Perry graduated from pharmacy school at the University of the Pacific in 1969.  He received his PhD in Pharmacy from Pacific in 1973.  He went to the University of Iowa in 1973 as an assistant professor in the College of Pharmacy.  He was one of the founding faculty for the Clinical Pharmacy program at Iowa.  He remained at Iowa for the next 32 years.  During this time he developed a national and international reputation for his research in clinical psychopharmacology.  He has authored more than 200 peer-reviewed publications.  His clinical reference book the Psychotropic Drug Handbook is in its 8th edition.  He is currently an emeritus professor of pharmacy and psychiatry in the Colleges of Pharmacy and Medicine respectively at the University of Iowa.  He returned to California in 2005 to become one of the founding faculty for Touro Univeristy-California College of Pharmacy.   He is currently professor and chairman of the Pharmacy Practice Department at Touro.  He is also a member of the Medi-Cal Drug Use Board after serving on the Medicaid Drug Utilization Commission in Iowa for 14 years.  He co-teaches and precepts an APPE in Forensic Toxicology.  He has served as an expert witness for civil and criminal forensic cases since 1975.

Institution Degree Field of Study Obtained
University of the Pacific B.S. Pharmacy 1969
University of the Pacific M.S. Hospital Pharmacy 1971
University of the Pacific Ph.D. Clinical Pharmacy 1973

Fall Semester 
PHRM 604 Clinical Sciences 1 (Mental Status Exam, Substance Abuse, 15 contacts hours) 
PHRM 608: Clinical Sciences 2 (Drug Interactions, 6 contact hours) 
PHRM 612 Clinical Sciences 3 (Schizophrenia, Major Depression, Bipolar Disorder, Anxiety Disorders, and ADHD pharmacotherapy, 15 contacts hours 
PHRM 864 Forensic Toxicology, 72 contacts hours 

Over the past 35 years my research focus has centered in clinical psychopharmacology. I have conducted clinical trials that have spanned 1) pharmacokinetic dosing of psychotropic drugs including mood stabilizers, antidepressants, and antipsychotics, 2) pharmacogenetics of these agents, and 3) pharmaco-epidemiology studies that have investigated prescribing patterns and adverse effects being purportedly caused by psychotropic drugs. The interest in pharmaco-epidemiology stemmed from serving as a commissioner on the Iowa Medicaid Drug Utilization Commission for 14 years.  Additionally, in the area of substance abuse my primary area of study involves the use and abuse of performance enhacing drugs and the effects of drugs on driving.  I have a career long interest in post-graduate pharmaceutical education. I have been the preceptor for 11 Master’s degree (Clinical Pharmacy) graduate students and 13 Post-PharmD research fellows (Clinical Psychopharmacology).

1975 Establishment of clinical pharmacy services on the psychiatry service of Iowa City VA Hospital. VA, Principal Investigator. 


1977 Psychostimulant use as a precipitant of psychoses in predisposed individuals. University of Iowa, Psychiatry Department, Co-Principal Investigator. 

1978 Prophylactic efficacy of lithium carbonate versus tricyclic antidepressants following ECT in the treatment of depression. Iowa Mental Health Authority, $3,000, Co-Principal Investigator. 

1981 The relationship of free nortriptyline levels to antidepressant response. University of Iowa, Psychiatry Department, Principal Investigator. 

1981 Theophylline-Lithium Drug Interaction Study. University of Iowa Clinical Research Center-NIH Grant, Principal Investigator. 

1981 Evaluation of a hydrochlorothiazide-imipramine drug-drug interaction. NIH Junior Faculty Seed Grant, Investigator. 

1982 Theophylline precipitated alterations of lithium clearance. University of Iowa, Psychiatry Department, Principal Investigator 

1983 Oxaprotilene, double blind comparative efficacy and tolerability study with placebo in known alcoholic patients with a depressive episode of moderate severity. Ciba-Geigy, Investigator. 

1983 Prospective testing of the nortriptyline free therapeutic window. Eli Lilly, Principal Investigator. 

1985 Cost-Benefit analysis of prospective pharmacokinetic dosing of nortriptyline. Veterans Administration, Principal Investigator. 

1985 The cost-benefit implications of using tricyclic antidepressants blood levels in depressed inpatients. Sandoz Pharmaceuticals, Principal Investigator. 

1986 Fluoxetine versus trazodone in depressed adult patients. Eli Lilly, Co-Principal Investigator. 

1986 Plasma fluoxetine and norfluoxetine concentrations/ therapeutic response relationship. Eli Lilly, Principal Investigator. 

1986 Efficacy and tolerability of clomipramine (Anafranil) versus placebo in obsessive-compulsive disorder. Ciba-Geigy, Investigator. 

1987 Neurobiology and phenomenology of major psychoses. National Institute of Mental Health. N.C. Andreasen, M.D., Principal Investigator. P.J. Perry, Director, Neuropharmacology Unit. 

1988 Evaluation of the efficacy and cost of plasma haloperidol monitoring, Veterans Administration, Co-Investigator. 

1990 A placebo controlled dose response study of CI-943 in hospitalized chronic schizophrenic patients in acute exacerbation, Parke-Davis Pharmaceutical Co, Co-Principal Investigator. 

1991 LY170053 (Olanzapine) versus haloperidol and placebo in the treatment of schizophrenia. Eli Lilly and Co., Investigator. 

1991 Fluoxetine in patients with post-stroke depression. Eli Lilly and Co., Co-Investigator. 

1992 Mechanisms of ACTH regulation: medication effect. NIMH, R.G. Kathol, Principal Investigator, P.J. Perry, Investigator. 

1993 Response prediction and haloperidol plasma levels in schizophrenia. NIMH, $475,367. W.H. Coryell, M.D., Principal Investigator, P.J. Perry, Co-Investigator. 

1993 A pilot study of saliva cyclosporine concentration monitoring: its clinical utility in renal transplantation. NIH Junior Faculty Seed Grant, D.I. Min, Pharm.D., M.S., Principal Investigator, P.J. Perry, Co-Investigator. 

1993 A multicenter study to evaluate the efficacy, safety, and tolerability of zotepine hydrochloride 75, 150, and 300 mg daily doses in the treatment of acute schizophrenia. Boots Pharmaceuticals, Co-Principal Investigator. 

1993 An optional multicenter open-label long-term study to evaluate the efficacy, safety, and tolerability of zotepine hydrochloride 75, 150, and 300 mg daily doses in the treatment of schizophrenia. Boots Pharmaceuticals, Co-Principal Investigator. 

1993 Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Eli Lilly and Co, Co-Principal Investigator. 

1993 Fluvoxamine in the treatment of obsessive compulsive disorder. A multicenter double-blind placebo-controlled study in outpatient children and adolescents. Solvay Pharmaceuticals, Co-Investigator. 

1994 Psychoendocrinology of Anabolic Steroid Cycling. NIDA. P.J. Perry, Principal Investigator. 

1996 Pfizer Drug Formulary System Data Collection Project Consultation. Pfizer, Inc., P.J. Perry, PI. 

1996 Risperidone versus Clonidine in the Treatment of Tourette’s Syndrome. The Tourette’s Foundation., $25,000, and Jannsen Pharmaceuticals. P.J. Perry, Co-Investigator. 

1996 Bupropion vs Methylphenidate vs Placebo in the Treatment of Adult ADHD. Glaxo-Wellcome, Paul Perry, PI. 

1997 5-HT2A Receptor Polymorphism Responsible for Predicting Clinical Response to the Antipsychotic Agent Olanzapine. Investigator Initiated Protocol. Lilly, Paul J. Perry, PI. 

1997 Fluoxetine versus Placebo in Childhood/Adolescent Depression. Lilly, Paul J Perry, Investigator. 

1998 Effects of the Iowa Medicaid Mental Health Access Plan on Psychotropic Drug Use and Expenditures Investigator Initiated Protocol. Pfizer, Paul J. Perry, Co-Principal Investigator 

1999 Randomized, double-blind, placebo-controlled, variable discontinuation study of tomoxetine hydrochloride in children with attention deficit/hyperactivity disorder. Lilly, Paul J Perry, Co-Prinicipal Investigator. 

2000 A phase III randomized, double-blind comparison of placebo and tomoxetine hydrochloride in adult outpatients with DSM-IV attention-deficit/hyperactivity disorder. Lilly. Paul J Perry, Co-Principal Investigator. 

2000 A multicenter, randomized, double-blind safety and tolerability study of flexible doses of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Bristol-Myers Squib. Paul J Perry, Co-Principal Investigator. 

2000 Placebo-controlled olanzapine monotherapy in the treatment of Bipolar I Depression. Lilly. Paul J Perry, Co-Principal Investigator. 

2002 Bupropion in the Treatment of Pathological Gambling. National Institute of Drug Abuse 
(1R21MH63289-01A1). Donald Black, M.D., Principal Investigator. P.J. Perry, Co-Investigator, 33% salary 

2002 Detection of Drug-Induced Delirium. Gerontological Nursing Interventions Research Center and the Hartford Center for Geriatric Nursing Excellence, $11,880 Ryan Carnahan, Pharm.D., Principal Investigator, P.J. Perry, Co-Investigator. 

2004 Diabetes Prevalence Estimates in Schizophrenia and Risk Factor Assessment, Lilly,. P.J. Perry, Principal Investigator. 

2004 Atypical antipsychotic prescribing patterns and estimating the costs of various practices in the Iowa Medicaid population, Iowa Pharmacy Foundation. P.J. Perry, Principal Investigator. 

2004 An open label trial of aripiprazole in the treatment of conduct disorder in adolescents. Investigator Initiated Trial, $48,000, Bristol-Myers Squibb. P.J. Perry, Principal Investigator. 

2005 Risk of Cerebrovascular Events Associated with Antipsychotic Use in Patients with Dementia: A Large Retrospective VA/Medicare Merged Database Analysis, Lilly Investigator Initiated Trial, P.J. Perry and M. Barnett Co- Principal Investigator. 

2007 A Phase I/II Safety and Efficacy Study with Intra-Patient Dose Escalation of Lithium in Progressive Supranuclear Palsy (PSP) or Cortical Basal Syndrome (CBS) Subjects (NPTUNE 03). Subcontract Agreement under NINDS Contract # NO!-NS-4-2361, NPTUNE, Westat Subcontract No 8079-S16, Investigator. 

Books and Book Chapters (n=25) 

  1. Perry PJ, and Liskow BI.  Psychotropic Drug Formulary and Handbook, 1st edition, Iowa City: University of Iowa, 1976 
  2. Liskow BI, Perry PJ, and Alexander B.  Psychotropic Drug Handbook 2nd edition, Iowa City: University of Iowa, 1977.
  3. Perry PJ, Alexander B, and Liskow BI.  Psychotropic Drug Handbook 3rd edition, Cincinnati: Harvey Whitney Books, 1981.
  4. Perry PJ, Alexander B, and Liskow BI.  Psychotropic Drug Handbook, 4th edition, Cincinnati: Harvey Whitney Books, 1985.
  5. Alexander B, Perry PJ.  Diuretics. In: Johnson FN, ed. Lithium Combination Treatment.  London: Karger, 1987.
  6. Perry PJ, Alexander B.  Dosage and serum levels.  In: Johnson FN, ed. Modern Lithium Therapy.  Lancaster, England: MTP Press, 1987.
  7. Perry PJ, Alexander B, and Liskow BI.  Psychotropic Drug Handbook, 5th edition, Cincinnati: Harvey Whitney Books, 1988.
  8. Perry PJ, Alexander B.  The prospective prediction of individualized serum lithium concentration in acute mania.  In: Birch NJ, ed.  Proceedings of the Second British Lithium Congress.  Wolverhampton, England: IRL Press, 1988
  9. Holstad SG, Perry PJ, Kathol RG, Carson RW, Krummel SJ.  The effects of intravenous theophylline infusion versus intravenous sodium bicarbonate infusion on lithium clearance in normal subjects.  In: Birch NJ, ed.  Proceedings of the Second British Lithium Congress.  Wolverhampton, England: IRL Press, 1988
  10. Perry PJ, Garvey MJ, Noyes R.  Benzodiazepine treatment of generalized anxiety disorder.  In: Noyes R, Roth M, Burrows GD, eds.  Handbook of Anxiety - Volume 4: The Treatment of Anxiety.  Amsterdam: Elsevier Science Publishers, 1990.
  11. Perry PJ, Alexander B, and Liskow BI.  Psychotropic Drug Handbook, 6th edition, Cincinnati: Harvey Whitney Books, 1991.
  12. Perry PJ.  Lithium clinical pharmacokinetics.  In: Thellier M, Wissocq JC, eds.  Lithium Kinetics.  London: Karger, 1992.
  13. Perry PJ.  Smith DA.  Neuroleptic Plasma Concentrations: An Estimate Of Their Sensitivity and Specificity As Predictors of Response.   In Clinical Use of Neuroleptic Plasma Levels, SR Marder, JM Davis, PM Janicak, eds., Washington, D.C.: American Psychiatric Association, 1993.
  14. Perry PJ.  Miller DD.  The Clinical Utility of Clozapine Plasma Concentrations.  In Clinical Use of Neuroleptic Plasma Levels, SR Marder, JM Davis, PM Janicak, eds., Washington, D.C.: American Psychiatric Association, 1993.
  15. Perry PJ, Alexander B, Garvey MJ.  Pharmacotherapy of Psychiatric Illnesses.  In Winokur G, Clayton P, eds.  The Medical Basis of Psychiatry.  Philadelphia: W.B. Saunders, 1994.
  16. Zeilmann, C, Perry PJ.  Robinson RG.  Medications and their Effects  In Head Injury and Postconcussive Syndrome, M Rizzo and D Tranel, eds., New York: Churchill-Livingston, 1996
  17. Perry PJ, Alexander B, and Liskow BI.  Psychotropic Drug Handbook, 7th edition.  Washington, D.C., American Psychiatric Press, 1997.
  18. Perry PJ, Alexander B, Bever KA.  Serum level monitoring strategies.  In Psychiatric Treatment of the Medically Ill, Robinson RG and Yates WR, editors, New York, Marcel Deker, 1999
  19. Perry PJ. Psychotropic Agents  in Quick Reference to Pharmacokinetics.  Schoenwald RD, ed. Lancaster, PA,Technomic Publishing, 2002.Perry PJ. Psychotropic Agents.  In Pharmacokinetics in Drug Discovery and Development. Schoenwald RD, ed. Lancaster, PA, CRC Press 2002.
  20. Perry PJ.  Ethanol forensic pharmacology.  In Perception, Reaction, and Conspicuity. McLay RW, Wilder DG, eds. Iowa City, IA, University of Iowa, College of Law, 2003.
  21. Perry PJ, Alexander B, Liskow BI, DeVane, CL.  Psychotropic Drug Handbook, 8th edition.  Baltimore, MD, Lippincott, Williams and Wilkins, 2006.
  22. Perry P, Wehring H, Alexander B, Liskow B.  Clinical psychopharmacology and other somatic therapies.  In Fatemi SH, Clayton P, eds.  The Medical Basis of Psychiatry.  Totowa, NJ: Humana, Press 2007.
  23. Perry PJ, Kuperman S.  Attention-deficit Hyperactivity Disorder in Children, Adolescents and Adults.  In Koda-Kimble et al, eds.  Applied Therapeutics: the Clinical Use of Drugs, 9th edition.  New York City, Livingston, Williams, and Wilkins 2008.
  24. Tallian, KB, Perry PJ, Kuperman S, Finley PR.  Attention-deficit Hyperactivity Disorder in Children, Adolescents and Adults.  In Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, eds.  Applied Therapeutics: the Clinical Use of Drugs, 10th edition.  New York City, Livingston, Williams, and Wilkins 2011.

Refereed Original Research Publications (n=113) 

1. Perry PJ, Herron GR, King JC. Heparin half-life in normal and impaired renal function. Clinical Pharmacology and Therapeutics 1974;16:514-9. 

2. Juhl RP, Perry PJ, Norwood GJ, Martin LR. The family practitioner-clinical pharmacist group practice: a model clinic. Drug Intelligence and Clinical Pharmacy 1974;8:572-5. 

3. Perry PJ, Hurley SC. Activities of the clinical pharmacist in the office of a family practitioner. Drug Intelligence and Clinical Pharmacy 1975;9:129-33. 

4. Juhl RP, Tsuang MT, Perry PJ. Concomitant administration of haloperidol and lithium carbonate in acute mania. Diseases of the Nervous System 1977;38:675-6. 

5. Perry PJ, Wilding DC, Fowler RC, Hepler CD, Caputo JF. The absorption of oral and intramuscular chlordiazepoxide in alcoholics. Clinical Pharmacology and Therapeutics 1978,23:535-41. 

6. Perry PJ, Tsuang MT. Treatment of unipolar depression following electroconvulsive therapy. Relapse rate comparisons between lithium and tricyclics (therapies following ECT). Journal of Affective Disorders 1979;1:123-9. 

7. Perry PJ, Stambaugh RL, Tsuang MT, Smith RE. Sedative-hypnotic tolerance testing and withdrawal comparing diazepam to barbiturates. Journal of Clinical Psychopharmacology 1981;1:289-296. 

8. Perry P, Hahn R, Dunner F, Tsuang M, Berg M. Lithium kinetics in single daily dosing. Acta Psychiatrica Scandinavica 1981;64:281-94. 

9. Perry PJ, Alexander B, Dunner FJ, Schoenwald RD, Pfohl B, Miller D. Pharmacokinetic protocol for predicting serum lithium levels. Journal of Clinical Psychopharmacology 1982;2:114-8. 

10. Perry PJ, Morgan D, Smith,RE Tsuang MT. Treatment of unipolar depression accompanied by delusions: ECT vs tricyclic antidepressant-antipsychotic combination therapy. Journal of Affective Disorders 1982;4:195-200. 

11. Perry PJ, Prince RA, Alexander B. Prediction of lithium maintenance doses using a single-point prediction protocol. Journal of Clinical Psychopharmacology 1983;3:137. 

12. Taylor JT, Murphy MJ, Berg MJ, Perry PJ, Lyon LN, Ludden TM. Phenytoin dosage requirements and pharmacokinetic parameters. Clinical Pharmacy 1983;2:253-7. 

13. Alexander B, Nasrallah H, Perry P, Liskow B, Dunner F. The impact of psychopharmacology education on prescribing practices. Hospital and Community Psychiatry 1983;12:1150-53. 

14. Browne JL, Perry PJ, Alexander B, Sherman AD, Tsuang MT, Dunner FJ. Pharmacokinetic protocol for predicting plasma nortriptyline levels. Journal of Clinical Psychopharmacology 1983;3:351-5. 

15. Perry PJ, Smith RE, Calloway RA, Cook BL. Theophylline precipitated alterations of lithium clearance. Acta Psychiatrica Scandinavica 1984;69:528-37. 

16. Perry PJ, Browne JL, Alexander B, Sherman AD, Tsuang MT, Dunner FJ. The sensitivity of nortriptyline prospective kinetic dosing methods: one point versus multiple point methods. Clinical Pharmacokinetics 1984;9:555-63. 

17. Browne JL, Perry PJ, Taylor JW, Sieleni BA, Kronfol Z. Dose-dependent nortriptyline kinetics: a case report. Journal of Clinical Psychopharmacology 1984;4:322-25. 

18. Perry PJ, Alexander B, Prince RA, Dunner FJ. Prospective evaluation of two lithium maintenance dose schedules. Journal of Clinical Psychopharmacology 1984;4:242-46. 

19. Richards ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. Journal of Clinical Psychiatry 1985;46:67-71. 

20. Simmons SA, Perry PJ, Browne JL, Rickert ED. Cost-benefit analysis of pharmacokinetic dosing of nortriptyline in depressed inpatients. Journal of Affective Disorders 1985;8:47-53. 

21. Perry PJ, Browne JL, Alexander B, Pfohl BM, Sherman AD, Dunner FJ, Tsuang MT. The relationship of free nortriptyline levels to antidepressant response. Acta Psychiatrica Scandinavica 1985;72:120-25. 

22. Perry PJ, Alexander B, Prince RA, Dunner FJ. A single point dosing protocol for predicting steady state lithium levels. British Journal of Psychiatry 1986;148:401-5. 

23. Perry PJ, Browne JL, Prince RA, Alexander B, Tsuang MT. The effects of smoking on nortriptyline plasma levels in depressed patients. Therapeutic Drug Monitoring 1986;8:279-84. 

24. Perry PJ, Pfohl BM, Holstad SG. The relationship between pharmacologic response and tricyclic antidepressant drug disposition. A critique of the literature using logistic regression analysis. Clinical Pharmacokinetics 1987;13:381-92. 

25. Beeghly JHL, Kuperman S, Perry PJ, Wright GJ, Tsai LY. Fenfluramine treatment of autism: Relationship of treatment response to blood levels of fenfluramine and norfenfluramine. Journal of Autism and Developmental Disorders 1987;17:541-8. 

26. Perry PJ, Pfohl BM, Kelly MW. The relationship of haloperidol disposition and therapeutic response: an analysis of the literature using logistic regression analysis. Journal of Clinical Psychopharmacology 1988;8:34-40. 

27. Holstad SG, Perry PJ, Kathol RG, Carson RW, Krummel MD. The effects of intravenous theophylline infusion versus sodium bicarbonate infusion on lithium clearance in normal subjects. Psychiatry Research 1988;25:203-11. 

28. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry PJ, Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Annals of Internal Medicine 1989;110:108-14. 

29. Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depressive disorder. Journal of Clinical Psychiatry 1989;50:290-4. 

30. Kelly MW, Perry PJ, Holstad SG, Garvey, MJ. The relationship of fluoxetine plasma concentrations to therapeutic response. Therapeutic Drug Monitoring 1989;11:165-70. 

31. Garvey MJ, Schaffer C, Schaffer L, Perry PJ. Is DST status associated with depression characteristics? Journal of Affective Disorders 1989;16:159-65. 

32. Andersen KH, Perry PJ, Sherman AD, Kathol RG. Behavioral performance of lithium intoxicated Sprague-Dawley rats treated with theophylline. Psychiatry Research 1989;30:77-82. 

33. Fudge JL, Perry PJ, Garvey MJ, Kelly MW. The effect of fluoxetine and trazodone on memory in depressed outpatients. Journal of Affective Disorders 1990;18:275-80. 

34. Miller DD, Perry PJ, Kelly MW, Coryell WH. Pharmacokinetic protocol for predicting plasma haloperidol concentrations. Journal of Clinical Psychopharmacology 1990;10:207-12. 

35. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes: a case series analysis. American Journal of Sports Medicine 1990;18:422-8. 

36. Perry PJ, Yates WR, Andersen KH. Psychiatric symptoms associated with anabolic steroids: a controlled retrospective study. Annals of Clinical Psychiatry 1990;2:11-9. 

37. Myers CW, Perry PJ, Kathol RG. Plasma and erythrocyte serum lithium concentrations before and after chronic oral verapamil. Lithium 1990;1:49-53. 

38. Yates WR, Perry PJ, Anderson KH. Illicit anabolic steroid use: a controlled personality study. Acta Psychiatrica Scandinavica 1990;81:548-50. 

39. Perry PJ, Garvey MJ, Dunner D, Rush J, Kyhl J. Abnormal laboratory findings following a 6-week trial of trazodone and fluoxetine. Therapeutic Drug Monitoring 1990;12:517-20. 

40. Miller DD, Kelly MW, Perry PJ, Coryell WH. The effects of smoking on haloperidol clearance: single versus chronic dosing. Biological Psychiatry 1990;28:529-31. 

41. Coryell WH, Kelly MW, Perry PJ, Miller D. Haloperidol plasma levels and acute clinical change in schizophrenia. Journal of Clinical Psychopharmacology 1990;10:397-402. 

42. Williams JW Jr, Mutgi A, Noyes R, Perry P, Kathol R. Comparison of urinary free cortisol in depressed and non-depressed patients with malignancy. Biologic Psychiatry 1990;28:522-5. 

43. Kathol RG, Noyes R Jr, Williams J, Mutgi A, Perry P. Diagnosing depression in patients with medical illness. Psychosomatics 1990;31:434-40. 

44. Kelly MW, Perry PJ, Coryell WH, Miller DD. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Psychopharmacology 1990;102:514-20. 

45. Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and n-desmethylclozapine in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring 1991:13:69-72. 

46. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. American Journal of Psychiatry 1991;148:231-5. 

47. Garvey M, Wakefield D, Perry P, Dysken M, McGraw R, Loughlin P, Jordan W. Monitoring of haloperidol plasma levels in outpatient schizophrenics. Annals of Clinical Psychiatry 1992;4:121-6. 

48. Yates WR, Perry PJ, Murray S. Aggression and hostility in anabolic steroid users. Biological Psychiatry 1992;31:1232-4. 

49. Clem JR, Murry DJ, Perry PJ, Alexander B, Holman T. Student performance in a clinical pharmacy clerkship: computer-aided insturction versus traditional lectures. American Journal of Pharmaceutical Education 1992;56;259-63.

50. Perry PJ, Miller DD, Arndt SV, Holman TL. Haloperidol dosing requirements: the contribution of smoking and non-linear pharmacokinetics. Journal of Clinical Psychopharmacology 1993; 13:46-51. 

51. Miller DD, Perry PJ, Cadoret RJ, Andreasen NJ. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comprehensive Psychiatry 1994;35:8-15. 

52. Perry PJ, Arndt S, Zeilman C. Tricyclic antidepressant plasma concentrations: an estimate of their sensitivity and specificity as a predictor of response. Journal of Clinical Psychopharmacology 1994;14:230-240. 

53. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a followup study. Journal of Clinical Psychiatry 1994:559(suppl B):117-121. 

54. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Herman KJ, Schumacher S. Bupropion versus methylphenidate in the treatment of attention deficit hyperactivity disorder. Journal of the Academy of Adolescent and Child Psychiatry 1995;4:649-657. 

55. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in young healthy men. Journal of Urology 156 1996;2(part1):438-41. 

56. Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MA, Hunsicker LG. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996;62:123-25. 

57. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine HGAD Study Group (PJ Perry member). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123 

58. Ellingrod VL, Perry PJ, Crowe RR. Polymorphism of cytochrome P4502D6 in schizophrenics and normals controls. Psychiatric Genetics 1996;6:139. 

59. Ellingrod VL, Perry PJ, Yates WR, MacIndoe WR, Watson G, Arndt S, Holman TL. The effects of anabolic steroids on driving performance as assessed by the Iowa Driver Simulator. American Journal of Drug and Alcohol Abuse 1997;23:623-36. 

60. Perry PJ, MacIndoe WR, Yates WR, Scott SD, Holman TH. Detection of anabolic steroid administration: the urinary testosterone to epitestosterone ratio versus the urinary testosterone to luteinizing hormone ratio. Clinical Chemistry 1997;43:731-5. 

61. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenics. Journal of Clinical Psychopharmacology 1997;17:472-7. 

62. Combs MD, Perry PJ, Bever, KA. Desmethylclozapine: an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy 1997;17:1300-4. 

63. MacIndoe JH, Perry PJ, Yates WR, Holman TL, Ellingrod VL, Scott SD. Testosterone suppression of the HPT axis. Journal of Investigative Medicine 1998;45:441-7. 

64. Cooper CS, Perry PJ, Sparks AET, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. Journal of Urology 1998;159:441-3. 

65. Min DI, Perry PJ, Chen HY, Hunsicker LG. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity at different time points after renal transplantation. Pharmacotherapy 1998;18:282-7. 

66. Coryell WH, Miller DD, Perry PJ. Haloperidol plasma levels and dose optimization. American Journal of Psychiatry1998;155:48-53. 

67. PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations. Biological Psychiatry 1998;44:733-8. 

68. Yates WR, Perry PJ, MacIndoe JH, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biological Psychiatry 1999;45:254-60. 

69. Long TD, Ellingrod VL, Kathol RG, Christensen LE, Resch DS, Perry PJ. Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induce hypoglycemia.. Clinical Endocrinology 2000;52:781-7. 

70. Perry PJ, Bever-Stille KA, Arndt S, Gundersen S. Valproate plasma concentrations to dose correlations in bipolar affective disorder. Journal of Clinical Psychopharmacology 2000;20:277-9. 

71. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American olanzapine trial. Journal of Clinical Psychopharmacology 2001:21:14-20. 

72. Perry PJ, Lund BC, Arndt S, Holman T, Bever-Stille KA, Paulsen J. Bioavailable testosterone as a correlate of cognition, psychological status, quality of life, and sexual function in aging males: implications for testosterone replacement. Annals of Clinical Psychiatry 2001;13:75-80. 

73. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension: a claims-based approach. Archives of General Psychiatry 2001;58:1172-1176. 

74. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, Holman TL, Moser DJ, Paulsen JS. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry 2001;13:129-134. 

75. Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's Syndrome. American Journal of Child and Adolescent Psychiatry 2002;41:330-6. 

76. Ellingrod VL, Perry PJ, Lund BC, Bever-Stille KA, Fleming F, Holman TL, Miller D. Serotonin 5-HT2A and 5-HT2C receptor polymorphism responsible for predicting clinical response to the antipsychotic agent olanzapine. Journal of Clinical Psychopharmacology 2002;22:622-4. 

77. Lund BC, Flaum, M, Adam, LA, Perry PJ. Psychiatric Prescribing Trends and Practices in Iowa's Prisons. Psychiatry Services 2002;53:1023-1024. 

78. Perry PJ, Yates WR, Williams RD, Andersen A, MacIndoes JH, Lund BC, Holman TL. Testosterone therapy in late-life major depression in males. Journal of Clinical Psychiatry 2002:63:1096-1102. 

79. Carnahan RM, Lund BC, Perry PJ, Culp KR, Pollock BG. The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacology Bulletin 2002:36:14-19. 
80. Lund BC, Chrischilles EA, Carter BL, Ernst ME, Perry PJ. Development of computer algorithm for defining a cross-sectional drug regimen from electronic pharmacy claims. Journal of Clinical Epidemiology 2003;56:802-806. 

81. Perry PJ, Kutscher, EC, Lund BC, Yates WR, Holman, TL, Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. Journal of Forensic Sciences 2003;48:646-51. 

82. Ellingrod VL, Perry PJ, Stille KA, Lund BL, Fleming F, Holman T, Miller DD 5HT2A Receptor Promoter Polymorphism, -1438G/A And Negative Symptom Response To Olanzapine In Schizophrenia. Psychopharmacology Bulletin 2003:37:109-112. 

83. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman T, Miller DD. Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics 2005;134B:76-78. 

84. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? Journal of the American Geriatrics Society 2004;52:2082-7. 

85. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters: an Internet survey of drug utilization. Clinical Journal of Sports Medicine 2005;15:326-30. 

86. Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL, Ellingrod VL, Miller D. The association of weight gain and olanzapine plasma concentrations. Journal of Clinical Psychopharmacology 2005;25:250-254, 

87. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. Increased risk of extrapyramidal side effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatrica Scandinavica 2006;113:135-41. 

88. Barnett MJ, Perry PJ, Alexander B, Kaboli, PJ. Risk of Mortality Associated with Typical Antipsychotics in an Acutely Ill VA Population: A Brief Report. Journal of Clinical Psychopharmacology 2006;26:182-7. 

89. Perry, PJ, Argo TR, Barnett MJ, Liesveld JL, Liskow B, Hernan JM, Trnka MG, Brason MA. The association of alcohol-induced blackouts and grayouts to blood alcohol concentrations. Journal of Forensic Sciences 2006;51:896-9. 

90. Barnett MJ, Perry PJ, Langstaff JD, Kaboli PH. Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector medicate HMOs. Journal of Managed Care 2006;12:362-70.

91. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. Journal of Clinical Pharmacology 2006;46:1481-6. 

92. Black DW, Arndt S, Coryell W, Argo T, Fortbush KT, Shaw M, Perry P, Allen J. Bupropion in the Treatment of Pathological Gambling: A Randomized, Placebo-Controlled, Flexible-Dose Study. Journal of Clinical Psychopharmacology 2007;27:143-150. 

93. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of anticholinergic burden: associations with serum anticholinergic activity. In Press: The Journal of Clinical Pharmacology 2006;46:1481-6. 

94. Barnett M, Argo T, Yankey J, Perry PJ. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors. Annals of Clinical Psychiatry 2006;18:1 

95. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA, Flaum M. Antipsychotic polytherapy in a state Medicaid program from 1990 to 2001. The Journal of the College of Psychiatric and Neurologic Pharmacists, available at: http://cpnp.org/_docs/FINALPrintPrerpCarnahan.pdf 

96. Barnett MJ, Kaboli, PJ, Alexander B, Perry PJ. Risk of Mortality Associated with Antipsychotic and Other Neuropsychiatric Drugs in Pneumonia Patients. Journal of Clinical Psychopharmacology 2006:26:182-7. 

97. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. Journal of Clinical Psychopharmacology 2007;27:595-601. 

99. Carnahan RM, Lund BC, Chrischilles EA, Perry PJ. Antidepressant adherence in a high risk clinical population. Research in Social and Administrative Pharmacy (in press). 

100. Perry PJ, Carnahan R, Argo T, Barnett M, Holman T. Diabetes prevalence estimates in schizophrenia and risk factor assessment. Journal of Clinical Psychopharmacology (submitted). 

101. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. Journal of Clinical Psychopharmacology 2007;27:595-601. 

102. Carnahan RM, Lund BC, Chrischilles EA, Perry PJ.  Consistency of antidepressant and chronic nonpsychiatric medication use in a high-risk clinical population.  Research in Social and Administrative Pharmacy 2008:4:367-374.

103. Barnett MJ, Frank J, Wehring H, Newland B, VonMuenster S, Kumbera P, Halterman T, Perry PJ.  Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.  Journal of Managed Care Pharmacy 2009;15:18-31.

104.  Ip EJ, Barnett MJ, Tenerowicxz, Perry PJ.  The Touro 12-step: A systematic guide to optimizing survey research with online discussion boards.  J Med internet Res 2010;12:e16

105.  Barnett MJ, VonMuenster SJ, Wehring HJ, Walker V, Perry PJ. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.  Annals of Clinical Psychiatry 2010; 22(1):9-18.

106.  Ip EJ, Barnett MJ, Tenerowicz MJ, Kim JA, Hong W, Perry PJ  Women and Anabolic Steroids: An Analysis of a Dozen Users. Clinical Journal of Sports Medicine 2010;20:475-481.

107.  Argo T, Carnahan R, , Barnett M, Holman T. Perry PJ.  Diabetes prevalence estimates in schizophrenia and risk factor assessment.  Annals of Clinical Psychiatry 2011 May;23(2):117-24

108.  Kuperman S, Calarge C, Kolar A, Holman T, Barnett M, Perry P. An open -label Trial of aripiprazole in the treatment of impulsive aggression in male Adolescents diagnosed with conduct disorder  Annals of Clinical Psychiatry  2011 :23 :270-6.

109.  Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The anabolic 500 survey : Characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training.  Pharmacotherapy 2011;31 :757-66.

110.  Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JD,  Perry PJ. Psychological  and physical impact of anabolic-androgenic steroid dependence.  Pharmacotherapy 2012;32:910-19.

111.   Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ.  Weightlifting’s risky new trend : a case series of 41 insulin users.  Current  Sports Medicine Reports 2012 ;11 :176-9

112.   Phan HM, Yoshizuka K, Murry DJ, Perry PJ.  Drug testing in the workplace.  Pharmacotherapy 2012;32 :649-56.

113. Ip EJ, BuiQV, Barnett MJ, Kaxani A, WrightR, Serino MJ, Perry PJ.  The effect of trazodone on standardized field sobrity tests.   Pharmacotherapy 2013;33:369-74.


Published reviews of scholarship (n=53) 

1. Perry PJ, Juhl RP. Amphetamine psychosis. American Journal of Hospital Pharmacy 1977;34:883-5. 

2. Fowler RC, Kronfol ZA, Perry PJ. Water intoxication, psychosis, and inappropriate secretion of antidiuretic hormone. Archives of General Psychiatry 1977;34:1097-9. 

3. Ponto, LB, Perry, PJ, Liskow, BI,Seaba, HH. Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Journal of Maine Medical Association, 1977;68:283-9. N Eng Med Center Hospital Forum 6:(Sept.) 1977. American Journal of Hospital Pharmacy, 1977;34:954-61. Drug Therapy Reviews, Volume 2, Elsevier/North Holland, New York, 1979, pp. 286-304. 

4. Perry PJ, Wilding DC, Juhl, RP. Anticholinergic psychosis. American Journal of Hospital Pharmacy 1978;35:725-7. 

5. Richards ML, Perry PJ. Phencyclidine psychosis. Drug Intelligence and Clinical Pharmacy 1979;13:336-9. 

6. Ling M, Perry PJ, Tsuang MT. Side effects of corticosteroid ther¬apy: psychiatric aspects. Archives of General Psychiatry 1981;38:471-7. 

7. Browne JL, Tsuang M, Perry P. Amoxapine neurotoxicity: a long-term follow-up. Drug Intelligence and Clinical Pharmacy 1982;16:404-7. 

8. Perry PJ, Lithium nephrotoxicity. Drug Intelligence and Clinical Pharmacy 1982;16:744-9. 

9. Perry PJ, Huang MH, Tsuang MT. Prednisolone psychosis: clinical observations. Drug Intelligence and Clinical Pharmacy 1984;18:603-8. 

10. Cook BL, Smith RE, Perry PJ, Calloway RA. Lithium/theophylline interaction. Journal of Clinical Psychiatry 1985;46:278-9. 

11. Perry PJ. Assessment of addiction liability of benzodiazepines and buspirone. Drug Intelligence and Clinical Pharmacy 1985;19:657-8. 

12. Noyes R, Perry PJ, Crowe RR, Coryell WH, Clancey J, Gabel J. Seizures following the withdrawal of alprazolam. Journal of Nervous and Mental Disease 1986;174,50-2. 

13. Perry PJ, Alexander B. Sedative/hypnotic dependence: patient tolerance testing, stabilization, and withdrawal. Drug Intelligence and Clinical Pharmacy 1986;20:532-7. 

14. True BL, Perry PJ, Burns EA. Profound hypoglycemia with the addition of a tricyclic antidepressant maintenance sulfonylurea therapy. American Journal of Psychiatry 1987;144:1220. 

15. Perry PJ, Alexander B. The rational use of antidepressants. Primary Care 1987;14:773-84. 

16. Noyes RN, Garvey MJ, Cook BL, Perry PJ. Benzodiazepine withdrawal: a review of the evidence. Journal of Clinical Psychiatry 1988;49:382-9. 

17. Schneider PJ, Perry PJ. Triazolam: an "abused drug" by the lay press? DICP, Annals of Pharmacotherapy 1990;24:389-92. 

18. Kathol RG, Noyes R Jr, Williams J, Mutgi A, Carroll B, Perry P. Diagnosing depression in patients with medical illness. Psychosomatics 1990;31:434-40. 

19. Noyes R Jr, Perry PJ. Maintenance treatment with antidepressants in panic disorder. Journal of Clinical Psychiatry 1990;51(suppl A):24-30. 

20. Alexander B, Perry PJ. Detoxification from benzodiazepines: schedules and strategies. Journal of Substance Abuse Treatment 1991;8:9-17. 

21. Perry PJ. The Clinical Rating Scales for the Assessment of Antidepressant Drug Therapy. American Journal of Pain Management 1992;2:8-12. 

22. Smith DA, Perry PJ. Ergogenic agents in athletic competition: the anabolic steroids. Annals of Pharmacotherapy 1992;26:520-8. 

23. Smith DA, Perry PJ. Ergogenic agents in athletic competition: growth hormone, stimulants, and blood doping. Annals of Pharmacotherapy 1992;26:653-9. 

24. Smith DA, Perry PJ. Non-neuroleptic treatment of agitation. DICP, Annals of Pharmacotherapy 1992;26:1400-8. 

25. Hoehns JD, Perry PJ. Zolpidem. A review of a non-benzodiazepine hypnotic in the treatment of insomnia. Clinical Pharmacy 1993;12:814-28. 

26. Graeber M, Hoehns B, Perry P. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Annals of Pharmacotherapy 1994;28:632-6. 

27. Ellingrod VL, Perry PJ. Venlafaxine. American Journal of Hospital Pharmacy 1994;51:3033-46. 

28. Perry PJ. Clinical use of the newer antipsychotic drugs. Amercian Journal of Health-System Pharmacy 1994;52(suppl 1):S9-S14. 

29. Ellingrod VL, Perry PJ. Nefazodone. American Journal of Health Systems Pharmacy 1995;52:2799-812. 

30. Perry PJ. Pharmacotherapy for major depression with melancholic features: tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders 1996;39:1-6. 

31. Bever KA, Perry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. American Journal of Health Systems Pharmacy 1997;54:2059-72. 

32. Bever KA, Perry PJ. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. American Journal of Health Systems Pharmacy 1998;55:1003-16. 

33. Bever KA, Perry PJ. The clinical implications of the selective serotonin reuptake inhibitor pharmacoeconomic evaluations in the treatment of depression. Psychiatry Practice 1998;5:76-82. 

34. Lund BC, Bever-Stille KA, Perry PJ. Testosterone and Andropause. The feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 1999;19:561-66. 

35. Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson’s disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy 1999;19:1437-8. 

36. Noyes R, Perry PJ. Benzodiazepine treatment of panic disorder. Essential Psychopharmacology 1999;3:1-27. 

37. Lund BC, Perry PJ. Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opinion in Pharmacotherapy 2000;1:305-23. 

38. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000;20:844-7. 

39. Lund BC, Perry PJ. Androgenic-anabolic steroids: an overview for clinicians [review]. Medscape; September 2000.

40. Lund BC, Perry PJ. Non-steroid performance enhancing agents in athletic competition: an overview for clinicians [review]. Medscape; September 2000. 

41. Lund BC, Perry PJ. Pharmacotherapy for schizophrenia [review]. The New York Health-System Pharmacist 2001;20:6-12. 

42. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic [review]. Pharmacotherapy 2001;21:717-730.. 

43. Hatch CD, Lund BC, Perry PJ. Failed rechallenge with quetiapine after neuroleptic malignant syndrome. Pharmacotherapy 2001;21:1003-1006. 

44. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacology Bulletin 2001;35:19-29. 

45. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a body-builder’s perspective for the clinician [review]. Sports Medicine 2002:32:285-296. 

46. Carnahan RM, Lund BC, Perry PJ, Pollock BG. A critical appraisal of the utility of the serum anticholinergic assay in research and clinical practice. Psychopharmacology Bulletin 2002;36:24-39. 

47. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel antipsychotic drug. Pharmacotherapy 2004;24:212-228. 

48. Carnahan RM, Perry PJ. Depression in elderly men: The role of testosterone in therapy. Drugs and Aging 2004:21:361-76. 

49. Suda DA, Schlickman PW, Perry PJ. The clinical dilemma of lithium-induced hyperparathyroidism in a treatment responsive patient: a case report. Annals of Clinical Psychiatry 2006;18:131-2. 

50. Perry PJ. Corticosteroid- and anabolic Steroid-induced mental status disturbances. Journal of Pharmacy Practice 2007;20:335-41.

51. Chou TI, Perry PJ.  Pharmacotherapy of bipolar depression. California Pharmacy 2011;58:24-27.

52.  Perry PJ, Wilborn CA. Serotonin syndrome versus neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management.  Annals of Clinical Psychiatry 2012;24:155-62.

Yoshizuka K, Perry PJ.  The association between pharmacologic drug intoxication and forensic-specific intent.  Journal of Pharmacy Practice 2012;25:50-60.

Letters and Editorials (n=13) 

1 McGee JL, Alexander B, Perry PJ. Lithium citrate-trifluoperazine concentrate physical incompatibility: effect on serum lithium levels. American Journal of Hospital Pharmacy (letter) 1980;37:1052. 

2. Grasso RA, Perry PJ, Sherman AD. Relationship between tranylcypromine dose and MAO inhibition. DICP, Annals of Pharmacotherapy (letter) 1991;25:99-100. 

3. Perry PJ, Alexander B. Switching haloperidol from the oral to intramuscular depot formulation. DICP, Annals of Pharmacotherapy (letter) 1991;25:1270. 

4. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine concentrations and clinical response in schizophrenia. American Journal of Psychiatry (letter) 1991;148:1406-7. 

5. Perry PJ, Smith DA. Triazolam: the never-ending story. DICP, Annals of Pharmacotherapy (editorial) 1991;25:1263-4. 

6. Hoehns JD, Perry PJ. Look again at information on zolpidem tartrate. American Journal of Hospital Pharmacy 1994;51:1354-7. 

7. Yates WR, Perry PJ, Ellingrod V. Narcissism and anabolic steroids. American Journal of Psychiatry (letter) 1996;153:1653. 

8. Ellingrod VL, Perry PJ. Reassessment of nefazodone. American Journal of Health Systems Pharmacy 1996;53:2343-4. 

9. Perry PJ, Sanger T, Beasley, CM. Plasma olanzapine and clinical response. Journal of Clinical Psychopharmacology 1999:19:193. 

10. Bever-Stille KA, Perry PJ. Benefits of olanzapine as first-line schizophrenia therapy. American Journal of Health Systems Pharmacy 1999;56:1559-64. 

11. Perry PJ. Therapeutic drug monitoring of atypical antipscyhotics. Is it of potential clinical value? CNS Drugs 2000;13:167-171. 

12. Lund BC, Perry PJ, Miller DD. Treatingdepression in schizophrenia [letter]. American Journal of Psychiatry 2001;158:1528. 

13. Carnahan RM, Lund BC, Perry PJ. Trial design questionable in ziprasidone versus olanzapine efficacy study in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2005:162:1391 

Unrefereed Publications (n=12) 

1. Perry PJ. The clinical pharmacist in ambulatory care. Hospital Pharmacy Notes, 3 (Oct.) 1974. 

2. Perry, PJ. Attacking rheumatoid arthritis. Drug Topics 1975;119:23. 

3. Perry PJ. Hypnotic-sedatives. Iowa Pharmacist 1976;31:10-1. 

4. Perry PJ. Depression and antidepressants. Pharmat, Inc 1986;12, no 6. 

5 Perry PJ. Benzodiazepine withdrawal. American Druggist 1989;199:62. 

6. Perry PJ. Generalized anxiety disorder: controversy in therapy. Pharmacy Times 1991;106-116. 

7. Perry PJ. Sports Medicine. Pharmat, Inc 1991;17, no 3. 

8. Yates WR, Perry PJ. Psychopharmacology and psychiatric aspects of anabolic steroid use. Audio Digest - Psychiatry volume 21, January 13, 1992. 

9. Perry PJ. Monitoring and Assessment of Depression. Pharmat, Inc.1994. 

10. Perry PJ, St Dennis CD. Cost-effective treatment of depression in the elderly. US Pharmacist March, 1999, pp 24-40. 

11. Pollack BG, Ereshefsky L, Perry PJ. Looking backward – The CYP450 Interactions. Psychiatric Update 19 (June), 1999. The American Academy of Clinical Psychiatrists and Washington University School of Medicine. 

12. Lund BC, Perry PJ. Depression Management. Pharmat, Inc 2000. 

American College of Clinical Pharmacy

California Society of Health-System Pharmacists

American Association of Colleges of Pharmacy

College of Psychiatric and Neurologic Pharmacists

Board of Pharmaceutical Specialties

1998 Board Certification: Board of Pharmaceutical Specialties - Psychiatric Pharmacy Practice (BCPP-496284); recertified 10/12 
1999 Fellow, American College of Clinical Pharmacy 

2013-Judith Saklad Memorial Award, College of Psychiatric and Neurologic Pharmacists

Employer Title From - To
University of the Pacific Instructor 1973
University of Iowa, College of Pharmacy Assistant Professor 1973-1978
University of Iowa, College of Pharmacy Associate Professor 1978-1987
University of Iowa, College of Pharmacy Professor 1987-2005
Iowa Medicaid Drug Utilization Commission Commissioner 1988-2002
University of Iowa, College of Medicine (Psychiatry) Adjunct Professor 1989-1993
University of Iowa, College of Medicine (Psychiatry) Professor 1993-2005
Touro University – California, College of Pharmacy Professor 2005-present
University of Iowa, College of Medicine (Psychiatry) Emeritus Professor 2005-present
University of Iowa, College of Pharmacy Emeritus Professor 2005-present
Napa State Hospital – Napa, California Psychopharmacology Consultant 2006-2009
California Dept of Health Care Services Member, Drug Utilization Review Board 2007 - 2010
Last Updated: 3/15/16